Skip to main content

Mild to Moderate Alzheimer's Disease

Neurology
6
Pipeline Programs
9
Companies
6
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
4
0
0
1
Early DiscoveryClinical DevelopmentMarket

Neurology is a $26.9B market dominated by a single blockbuster anticoagulant (ELIQUIS), representing a mature but consolidating therapeutic area.

$26.9B marketMature→ Stable30 products15 companies

Key Trends

  • Extreme market concentration: 68% of spending driven by one FXa inhibitor product
  • Psychiatric and migraine therapies emerging as secondary growth drivers
  • High clinical trial activity (8,279 trials) signals continued pipeline development

Career Verdict

Neurology offers solid career stability with good hiring demand, but limited upside growth—best suited for professionals seeking established market positions rather than emerging-area innovation.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1ELIQUISStable
$18.3B
Bristol Myers Squibb·Launch15.0yr
$1.8B
#3BRILINTAStable
$692M
AstraZeneca·Peak10.2yr
#4NUPLAZIDStable
$596M
$530M
Johnson & Johnson·Peak15.6yr

Drug Class Breakdown

FXa Inhibitors (anticoagulant)
$18.3B(68%)

market-defining single product

Dopamine/Serotonin Antagonists (psychiatric)
$2.4B(9%)

stable mature class

P2Y12 Receptor Antagonists (antiplatelet)
$692M(3%)

niche but stable

5-HT2A Inverse Agonists (psychiatric)
$596M(2%)

specialty indication focus

CGRP Receptor Antagonists (migraine)
$931M(3%)

emerging growth segment

Immunomodulators (MS)
$747M(3%)

stable with LOE risk

Other mechanisms
$2.6B(10%)

diverse small products

Career Outlook

Stable

Neurology represents a mature, cash-generative market with limited growth tailwinds but strong hiring stability. The dominance of ELIQUIS creates a bifurcated career landscape: high-opportunity positions in emerging segments (CGRP antagonists, psychiatric therapeutics) and commoditized roles in anticoagulant franchises. Job availability is solid but growth expectations should be tempered relative to oncology or immunology.

Breaking In

Entry-level professionals should target clinical operations or commercial support roles at J&J, AstraZeneca, or Sanofi to build domain expertise in neurology disease states and competitive dynamics.

For Experienced Professionals

Experienced professionals should prioritize emerging mechanism roles (CGRP, tau-targeting programs) or pivot to medtech/neurotech (Stryker, Medtronic) to capture higher growth and salary potential than traditional pharma incumbents.

In-Demand Skills

Medical Science Liaisons (MSL) for specialist engagementClinical trial operations expertisePsychiatric/neurodegenerative disease educationRegulatory affairs (given patent cliff activity)Commercial strategy around branded/generic transitions

Best For

Medical Science LiaisonCommercial Brand Manager (anticoagulant/psychiatric franchises)Clinical Operations ManagerRegulatory Affairs SpecialistClinical Development Manager (CGRP/immunomodulator pipelines)

Hiring Landscape

$100K-$199K

Neurology shows moderate but distributed hiring across pharma and medtech employers, with 4,186 total jobs listed. Commercial functions lead (947 roles, $169K avg), followed by clinical operations (467 roles, $132K avg), indicating bias toward commercialization over R&D. Takeda leads external hiring (762 jobs) with strong representation in contract research and CRO spaces.

4,186
Open Roles
5
Companies Hiring
5
Departments

Top Hiring Companies

762Growing
434Stable
302Stable

By Department

Commercial(23%)
$169K
Clinical Operations(11%)
$132K
Engineering(8%)
$199K
IT(4%)
$100K
Manufacturing(3%)
$170K

Commercial and clinical operations roles dominate, offering stable mid-career positions; engineering roles command premium salaries ($199K), suggesting strong device/neurotech hiring pockets.

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
1 program
1
Rivastigmine PatchPhase 4
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
AZD1446Phase 21 trial
Active Trials
NCT01039701Completed99Est. Jul 2010
Cognition Therapeutics
Cognition TherapeuticsPA - Pittsburgh
1 program
1
CT1812Phase 2
Nia Therapeutics
Nia TherapeuticsMA - Boston
1 program
1
CT1812Phase 21 trial
Active Trials
NCT03507790Completed153Est. May 2024
Gemvax & KAEL
Gemvax & KAELKorea - Seongnam
1 program
1
GV1001 PlaceboPhase 21 trial
Active Trials
NCT05189210Completed199Est. Apr 2025
Biomed
BiomedAustralia - Sydney
1 program
1
Exosomes derived from umbilical cord mesenchymal stem cell for intranasal dropPhase 1/21 trial
Active Trials
NCT07457125Not Yet Recruiting33Est. Dec 2028
Oryzon Genomics
Oryzon GenomicsMA - Cambridge
1 program
ORY-2001 Low dosePHASE_2
Genomics
GenomicsUK - Oxford
1 program
ORY-2001 Low dosePHASE_21 trial
Active Trials
NCT03867253Completed24Est. Nov 2020
Novartis
NovartisBASEL, Switzerland
1 program
Rivastigmine PatchPHASE_41 trial
Active Trials
NCT02703636Completed118Est. May 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
NovartisRivastigmine Patch
Gemvax & KAELGV1001 Placebo
GenomicsORY-2001 Low dose
Nia TherapeuticsCT1812
AstraZenecaAZD1446
BiomedExosomes derived from umbilical cord mesenchymal stem cell for intranasal drop

Clinical Trials (6)

Total enrollment: 626 patients across 6 trials

NCT02703636NovartisRivastigmine Patch

NextStep:Study to Evaluate Safety,Efficacy & Tolerability of Rivastigmine Patch in Mild to Moderate Alzheimer's Patients.

Start: May 2016Est. completion: May 2018118 patients
Phase 4Completed

GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD)

Start: Oct 2022Est. completion: Apr 2025199 patients
Phase 2Completed
NCT03867253GenomicsORY-2001 Low dose

Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease

Start: May 2019Est. completion: Nov 202024 patients
Phase 2Completed

A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.

Start: Oct 2018Est. completion: May 2024153 patients
Phase 2Completed

4 Week, Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease

Start: Dec 2009Est. completion: Jul 201099 patients
Phase 2Completed
NCT07457125BiomedExosomes derived from umbilical cord mesenchymal stem cell for intranasal drop

The Effect of CB-Exo-A600 in Mild to Moderate Alzheimer's Disease

Start: Mar 2026Est. completion: Dec 202833 patients
Phase 1/2Not Yet Recruiting

Related Jobs in Neurology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

9 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.